FindTrial
Sign In

Vistusertib

DRUG7 trials

Sponsors

M.D. Anderson Cancer Center, AstraZeneca, University of Birmingham, Gustave Roussy, Cancer Campus, Grand Paris, Acerta Pharma BV

Conditions

AdenocarcinomaBRCA1 Mutation CarrierBRCA2 Mutation CarrierCarcinoma, Squamous CellDLBCLEndometrial AdenocarcinomaEstrogen Receptor NegativeHER2/Neu Negative

Phase 1

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Active, not recruitingNCT02208375
M.D. Anderson Cancer CenterBRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma +13
Start: 2014-11-11End: 2026-06-30Updated: 2025-12-31
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Active, not recruitingNCT02546661
AstraZenecaMuscle Invasive Bladder Cancer
Start: 2016-12-28End: 2026-01-30Updated: 2025-12-29
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
RecruitingNCT02813135
Gustave Roussy, Cancer Campus, Grand ParisPediatric Cancer
Start: 2016-08-03End: 2031-02-01Target: 472Updated: 2026-01-16
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
TerminatedNCT03205046
Acerta Pharma BVDLBCL, Richter Syndrome
Start: 2017-06-29End: 2019-11-20Updated: 2021-01-06
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
TerminatedNCT03366103
National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm +6
Start: 2018-03-20End: 2022-09-21Updated: 2023-10-17

Phase 2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Active, not recruitingNCT02664935
University of BirminghamAdenocarcinoma, Carcinoma, Squamous Cell, Non-Small Cell Lung Cancer
Start: 2015-05-31End: 2025-09-30Updated: 2025-05-21
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Active, not recruitingNCT03334617
AstraZenecaNon-Small Cell Lung Cancer
Start: 2017-12-18End: 2026-09-11Updated: 2025-10-27

Related Papers

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
2025-03-114 citations
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.
2025-02-251 citations
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
The Oncologist2024-04-011 citations
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Nature Medicine2024-02-13100 citations
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
Journal of Clinical Investigation2023-11-0736 citations
695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
Regular and Young Investigator Award Abstracts2023-10-315 citations
Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)
Cancer Research2023-04-144 citations
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
OncoImmunology2022-06-1846 citations
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Cancer Discovery2022-03-16143 citations
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Leukemia & lymphoma/Leukemia and lymphoma2021-07-166 citations
Abstract LB016: Deep learning identifies pathobiological features within H&E images associated with genomic alterations and progression on anti-PD(L)1 in HUDSON, an AstraZeneca-sponsored Phase II clinical trial
Cancer Research2021-07-01
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
2021-05-2445 citations
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
2021-05-0384 citations
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
BMC Cancer2020-06-0535 citations
Systems approach to rational combination therapy: PARP inhibitors.
2020-06-0133 citations
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
2019-05-2938 citations
AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan.
Journal of Clinical Oncology2019-05-208 citations
Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.
Journal of Clinical Oncology2019-05-205 citations
EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM
Neuro-Oncology2018-06-01

6 more papers not shown